Source:http://linkedlifedata.com/resource/pubmed/id/11960289
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2002-4-17
|
| pubmed:abstractText |
The human colorectal carcinoma (CRC)-associated GA733 antigen (Ag), also named CO17-1A/EpCAM/KSA/KS1-4, has been a useful target in passive immunotherapy of CRC patients with monoclonal antibody (mAb) and in active immunotherapy with anti-idiotypic antibodies or with recombinant protein. These approaches have targeted single epitopes (monoclonal anti-GA733 antibodies and anti-idiotypic antibodies) or extracellular domain epitopes (recombinant protein), primarily by B cells. To determine whether a reagent that induces immunity to a larger number of both B- and T-cell epitopes might represent a superior vaccine, we analyzed the capacity of full-length GA733 Ag expressing multiple potentially immunogenic epitopes and encoded by recombinant vaccinia virus (VV GA733-2) to induce humoral, cellular, and/or protective immunity in mice. VV GA733-2 induced Ag-specific antibodies that reacted predominantly to unknown epitopes on the Ag and lysed Ag-positive CRC targets in conjunction with murine peritoneal macrophages as effector cells. Immunized mice developed Ag-specific, proliferative and delayed-type hypersensitive lymphocytes. VV GA733-2 inhibited growth of ras-transformed syngeneic tumor cells expressing the human GA733 Ag in mice. These results suggest the potential of VV GA733-2 as a candidate vaccine for patients with CRC, possibly in combination with recombinant GA733-2-expressing adenovirus, which has been shown to induce cytolytic antibodies and T cells as well as tumor protective effects in mice. The combined vaccine approach may be superior to the use of either vaccine alone in patients who are pre-immune to both viruses.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Cell Adhesion Molecules,
http://linkedlifedata.com/resource/pubmed/chemical/tumor-associated antigen GA733
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0929-1903
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
382-9
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:11960289-3T3 Cells,
pubmed-meshheading:11960289-Animals,
pubmed-meshheading:11960289-Antibodies, Monoclonal,
pubmed-meshheading:11960289-Antibody-Dependent Cell Cytotoxicity,
pubmed-meshheading:11960289-Antigens, Neoplasm,
pubmed-meshheading:11960289-Antigens, Viral,
pubmed-meshheading:11960289-Cell Adhesion Molecules,
pubmed-meshheading:11960289-Cell Division,
pubmed-meshheading:11960289-Female,
pubmed-meshheading:11960289-Gene Therapy,
pubmed-meshheading:11960289-Humans,
pubmed-meshheading:11960289-Hypersensitivity, Delayed,
pubmed-meshheading:11960289-Immunity, Cellular,
pubmed-meshheading:11960289-Lymphocyte Activation,
pubmed-meshheading:11960289-Mice,
pubmed-meshheading:11960289-Mice, Inbred BALB C,
pubmed-meshheading:11960289-Neoplasms, Experimental,
pubmed-meshheading:11960289-T-Lymphocytes,
pubmed-meshheading:11960289-Transfection,
pubmed-meshheading:11960289-Vaccinia virus
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice.
|
| pubmed:affiliation |
The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|